Health Technology Assessment

Canadian Cancer Action Network

and

CADTH_pCODR_logo_rgb copy

 

Welcome to the Cancer Drug Pipeline Information for Patient Advocacy Groups

Click here to access.

The Canadian Cancer Action Network (CCAN) and the pan-Canadian Oncology Drug Review (pCODR), a program of the Canadian Agency for Drugs and Technologies in Health (CADTH), are very pleased to introduce a central source of information on the anticipated cancer drug products/indications that could enter the Canadian market to support patient groups with longer lead times to make a submission to pCODR. 

The information in this document is intended to identify potential new cancer drug products or indications that could be submitted to the pCODR program in the near future. The published information is obtained from publicly available sources, including from US Food and Drug Administration. 

CCAN and CADTH do not represent or warrant that any of the drug products listed below will be submitted to the pCODR program.  The use of this information is solely intended for informational purposes to assist patient groups to be more informed about the anticipated cancer drug products/indications that are in the pipeline.  CCAN and CADTH do not in any way endorse any information, drugs, therapies, treatments, products, processes, or services, which may or may not be under review by Health Canada.

CCAN will make best efforts to ensure that the information and publications are accurate, complete and updated regularly.  CCAN will take steps to correct any errors and/or omissions that would be reported by a manufacturer or other stakeholders within a reasonable time period.  Any information available in this document may be changed at any time and without notice.

While CCAN, as the primary author of this information, seeks to provide the information included in this document truthfully, accurately, and without typographical errors, the information is provided “as is”; CCAN and CADTH are not responsible for any errors or omissions or injury, loss or damage arising from or relating to the use (or misuse) of any information, statements or conclusions contained in or implied by the information in this document.  Please refer to CADTH’s Terms of Use for additional clarity.

For inquiries, please contact info@canceraction.ca.